Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections

Figures & data

Figure 1 Drug satisfaction at T0 and T1 in percent.

Table 1 Patient Characteristics At T0

Age in years, median (IQR)	45 (38–51)
Disease duration in years, median (IQR)	19 (18–26)
Duration of i.v. belimumab-therapy in years, median (IQR)	4.0 (2.3–4.4)
HAQ, mean (SD)	0.71 (0.4)
SLEDAI-2k, median (IQR)	2 (0–4)
SDI, median (IQR)	1 (0–2)
ds DNA-antibody (ELISA), mean (SD)	354.9 (255.9)
C3c in mg/dL, mean (SD)	91.38 (18.2)
C4 in mg/dL, mean (SD)	16 (7.9)
WBC in 1000/µL, mean (SD)	5.9 (1.7)

Abbreviations: IQR, interquartile range; SD, standard deviation; SDI, SLICC ACR damage index; SLEDAI-2k, systemic lupus erythematosus disease activity index 2000l; WBC, white blood cells.

Table 2 Clinical Parameters And Functional Status At T0 (I.v. belimumab) And T1 (S.c. belimumab). Linear Regression Analysis Was Applied To Identify An Association Of Parameters With The Route Of Administration (I.v. vs. s.c.)

	i.v. (T0)	s.c. (T1)	p-value
HAQ, mean (SD)	0.71 (0.4)	0.62 (0.3)	p = 0.3
SLEDAI-2k, median (IQR)	2 (0–4)	2 (2–4)	p = 0.4
SDI, median (IQR)	1 (0–2)	1 (0–2)	p = 1.0
ds DNA-antibody (ELISA), mean (SD)	354.9 (255.9)	284.3 (261.0)	p = 0.014
C3c in mg/dL, mean (SD)	91.4 (18.2)	93.3 (18.1)	p < 0.0001
C4 in mg/dL, mean (SD)	16.0 (7.9)	16.9 (8.4)	p = 0.004

Note: p-values in bold indicate an impact of the administration route on the tested parameters, p<0.05.

Abbreviations: HAQ, health assessment questionnaire; IQR, interquartile range; SD, standard deviation; SDI, SLICC ACR damage index; SLEDAI-2k, systemic lupus erythematosus disease activity index 2000; WBC, white blood cells.